Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pasithea TherapeuticsKTTA -0.07%29 EV-to-OCF is 1.48 as of Sep. 07, 2026, which is 58% below its 10-year median of 3.53. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Pasithea Therapeutics ranks worse than 78.59% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Pasithea Therapeutics's Enterprise Value is $-26.28 Mil.
Pasithea Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-17.78 Mil. Therefore, Pasithea Therapeutics's EV-to-OCF for today is 1.48.
The historical rank and industry rank for Pasithea Therapeutics's EV-to-OCF or its related term are showing as below:
KTTA'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.76 Med: 3.53 Max: 9.3
Current: 1.48
During the past 6 years, the highest EV-to-OCF of Pasithea Therapeutics was 9.30. The lowest was 0.76. And the median was 3.53.
KTTA's EV-to-OCF is ranked worse than 78.59% of 1406
companies
in the Biotechnology industry
Industry Median: -3.7
vs KTTA: 1.48
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pasithea Therapeutics's PE Ratio (TTM) for today is calculated as:
Pasithea Therapeutics's share price for today is $0.58.
Pasithea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.128.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pasithea Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pasithea Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's EV-to-OCF falls into.
Pasithea Therapeutics's current Enterprise Value is $-26.28 Mil.
Pasithea Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics (KTTA) has a EV-to-OCF of 1.48 as of Sep. 07, 2026. This is 58% below median its historical median of 3.53. Over the past decade, Pasithea Therapeutics' EV-to-OCF has ranged from 0.76 to 9.30. According to the industry distribution chart, Pasithea Therapeutics ranks #1105 out of 1406 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Pasithea Therapeutics' EV-to-OCF too high?
Pasithea Therapeutics' current EV-to-OCF of 1.48 is 58% below median its 10-year median of 3.53. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 9.30. Based on the distribution chart, Pasithea Therapeutics ranks #1105 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' EV-to-OCF compare to PTN and BIVI?
According to the Biotechnology industry distribution chart, Pasithea Therapeutics ranks #1105 out of 1406 companies for EV-to-OCF. This places Pasithea Therapeutics in the lower half of its industry. Historically, Pasithea Therapeutics' own EV-to-OCF has ranged from 0.76 to 9.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Pasithea Therapeutics's current EV-to-OCF is 1.48, which is 58% below median its own 10-year median of 3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current EV-to-OCF of 1.48. The current EV-to-OCF is 1.48, which is 58% below median its 10-year median of 3.53. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current EV-to-OCF is 1.48 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score
Get the complete analysis for KTTA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KTTA has been successfully added to your 
